Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

NCT03866369 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: Moxifloxacin
DRUG: Placebo
DRUG: Lanifibranor
DRUG: Placebo

Sponsor

Inventiva Pharma

Collaborators

[object Object]